Evidence map›Paper›PMID 37500962›Full record

ArticleBreast cancer research and treatment2023

Quantifying hormone receptor status in lobular breast cancer in an institutional series: the relationship between estrogen and progesterone receptor status and outcomes.

Elle N Clelland, Harriet T Rothschild, Anne Patterson, Julissa Molina-Vega, Mandeep Kaur, W Fraser Symmans, Christopher J Schwartz, A Jo Chien, Christopher C Benz, Rita A Mukhtar

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Breast cancer research and treatment, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.0field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Pitfalls in the Histological Diagnosis of Morphologic Variants of Invasive Lobular Carcinoma of the Breast.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2025
    Review
  7. bioRxiv : the preprint server for biology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Elle N ClellandSchool of Medicine, University of California, San Francisco, San Francisco, CA, USA.ORCID http://orcid.org/0000-0003-1439-0532
Harriet T RothschildSchool of Medicine, University of California, San Francisco, San Francisco, CA, USA.ORCID http://orcid.org/0000-0001-5311-2872
Anne PattersonDepartment of Surgery, University of California, 1825 4th Street, 3rd Floor, Box 1710, San Francisco, CA, 94143, USA.ORCID http://orcid.org/0000-0002-1416-7376
Julissa Molina-VegaDepartment of Surgery, University of California, 1825 4th Street, 3rd Floor, Box 1710, San Francisco, CA, 94143, USA.
Mandeep KaurSchool of Medicine, University of California, San Francisco, San Francisco, CA, USA.ORCID http://orcid.org/0000-0002-5544-5918
W Fraser SymmansDepartment of Pathology, MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0002-1526-184X
Christopher J SchwartzDepartment of Pathology, University of California, San Francisco, San Francisco, CA, USA.ORCID http://orcid.org/0000-0002-8086-8429
A Jo ChienDepartment of Medicine, University of California, San Francisco, San Francisco, USA.ORCID http://orcid.org/0000-0003-2978-6249
Christopher C BenzCancer & Developmental Therapeutics Program, Buck Institute for Research on Aging, Novato, USA.
Rita A MukhtarDepartment of Surgery, University of California, 1825 4th Street, 3rd Floor, Box 1710, San Francisco, CA, 94143, USA. rita.mukhtar@ucsf.edu.ORCID http://orcid.org/0000-0001-8079-7846
University of California, San Francisco · USBuck Institute for Research on Aging · USThe University of Texas MD Anderson Cancer Center · US

Funding

Identifying responders to chemotherapy in invasive lobular carcinoma of the breast: development of a multivariable clinical prediction toolK08CA256047 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MUKHTAR, RITA · 2021 to 2025
$1.3M
NCI NIH HHS K08 CA256047
6 · The paper itself

Abstract

purposeRecent guidelines defined a new reporting category of ER-low-positive breast cancer based on immunohistochemistry (IHC). While low positivity of either hormone receptor is uncommon in invasive lobular carcinoma (ILC), we sought to investigate whether relatively low hormone receptor positivity was associated with tumor characteristics and patient outcomes in a single institutional cohort.

methodsWe searched an institutional database for cases of stage I-III ILC with available IHC reports. Based on prior published categories in ILC, ER was classified as low, medium, or high as defined by ER staining of 10-69%, 70-89%, and ≥ 90% respectively. PR low and high tumors were defined by < 20%, or ≥ 20% staining respectively. We used chi-squared tests, t-tests, and Cox proportional hazards models to evaluate associations between ER/PR categories and tumor characteristics or disease-free survival (DFS).

resultsThe cohort consisted of 707 ILC cases, with 11% of cases categorized as ER low, 15.1% as medium, and 73.8% as high. The majority (67.6%) were PR high. Patients with ER low/medium expression were significantly younger, and more likely to also have PR low and/or HER2 positive tumors compared to those that were ER high. In a Cox proportional hazards model adjusting for age, stage, grade, pleomorphic histology, and treatment, ER category was not prognostic for DFS, but PR negative and PR low status each had significantly worse DFS compared to PR high status (HR 3.5, 95% CI 1.8-6.7, p < 0.001; and HR 2.0, 95% CI 1.1-3.5, p = 0.015, respectively).

conclusionThese findings highlight the relevance of quantifying ER and PR within ILC.

Indexed as

Breast NeoplasmsCarcinoma, LobularBiomarkers, TumorErb-b2 Receptor Tyrosine KinasesEstrogensFemaleHumansPrognosisReceptors, EstrogenReceptors, ProgesteroneBiomarkers, TumorErb-b2 Receptor Tyrosine KinasesEstrogensReceptors, EstrogenReceptors, ProgesteroneBreast cancerEstrogenHormone receptorHormone receptor positivityImmunohistochemistryInvasive lobular carcinomaProgesterone

Identifiers

PMID37500962
PMCPMC10505592
OpenAlexW4385325665

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.